Overexpression of <em>HYOU1</em> is associated with cisplatin resistance and may depend on m<sup>6</sup>A modification in patients with cervical cancer

Wang,Ruixue; Deng,Jiaxing; Zhang,Meng; Wang,Zhihui; Wu,Shangjie; Liu,Shilong; Qi,Lishuang

doi:10.3892/ol.2024.14823

Overexpression of HYOU1 is associated with cisplatin resistance and may depend on m⁶A modification in patients with cervical cancer

Authors:
- Ruixue Wang
- Jiaxing Deng
- Meng Zhang
- Zhihui Wang
- Shangjie Wu
- Shilong Liu
- Lishuang Qi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Systems Biology, College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China, Department of Thoracic Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150086, P.R. China
Published online on: November 26, 2024 https://doi.org/10.3892/ol.2024.14823
Article Number: 77
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer (CC) is the fourth leading cause of cancer‑associated mortalities among women worldwide. The chemotherapeutical platinum‑based agent cisplatin (DDP) is the standard therapy for locally advanced or recurrent CC; however, platinum resistance limits its clinical benefit. Therefore, the present study aimed to identify key genes associated with DDP resistance in patients with CC and investigate the underlying molecular mechanisms. Firstly, using the CRISPR‑Cas9 dataset of CC cells derived from DepMap portal, 699 genes associated with CC cell survival were identified. Subsequently, using the gene expression profiles of normal and CC samples with a response status to DDP, derived from The Cancer Genome Atlas (TCGA), hypoxia upregulated 1 (HYOU1) was further identified as significantly upregulated in CC samples and patients that did not respond to DDP (non‑responders) when compared with healthy controls and patients that did respond to DDP (responders), respectively, using unpaired student's t‑tests. Additionally, the log‑rank test revealed that the high expression of HYOU1 was significantly associated with the poor survival of patients receiving DDP. The association between the high HYOU1 expression levels and the poor survival of patients receiving DDP was validated in the remaining TCGA dataset of patients with CC. HYOU1 expression levels were positively associated with the half‑maximal inhibitory concentration value of DDP in CC cells using data derived from the Genomics of Drug Sensitivity in Cancer database. In vitro, western blotting experiments revealed high HYOU1 protein expression levels in DDP‑resistant HeLa cells compared with their parental HeLa cells. Furthermore, the knockdown of HYOU1 resulted in an increased sensitivity of HeLa cells to DDP. Finally, using the sequence‑based RNA adenosine methylation site predictor program, it was found that N⁶‑methyladenosine (m⁶A) was highly enriched in HYOU1. The expression levels of the m6A reader, EIF3A, was positively correlated with the expression levels of HYOU1 and was upregulated in the non‑response group compared with the response group in a dataset from TCGA database. Additionally, EIF3A had the highest probability of binding to the m6A motifs of HYOU1 compared with other genes. In GSE56363 obtained from the Gene Expression Omnibus, the non‑responders had significantly increased expression levels of EIF3A compared with the responders. In conclusion, high expression levels of HYOU1, which may be regulated by EIF3A due to m⁶A modifications, was associated with DDP resistance in patients with CC and could potentially be used as an indicator of DDP treatment resistance.

View Figures

View References

1	Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
3	Zhu H, Luo H, Zhang W, Shen Z, Hu X and Zhu X: Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther. 10:1885–1895. 2016. View Article : Google Scholar : PubMed/NCBI
4	Lorusso D, Petrelli F, Coinu A, Raspagliesi F and Barni S: A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer. Gynecol Oncol. 133:117–123. 2014. View Article : Google Scholar : PubMed/NCBI
5	Kishimoto S, Kawazoe Y, Ikeno M, Saitoh M, Nakano Y, Nishi Y, Fukushima S and Takeuchi Y: Role of Na+, K+-ATPase alpha1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother Pharmacol. 57:84–90. 2006. View Article : Google Scholar : PubMed/NCBI
6	Bai ZL, Wang YY, Zhe H, He JL and Hai P: ERCC1 mRNA levels can predict the response to cisplatin-based concurrent chemoradiotherapy of locally advanced cervical squamous cell carcinoma. Radiat Oncol. 7:2212012. View Article : Google Scholar : PubMed/NCBI
7	Yang X, Fraser M, Abedini MR, Bai T and Tsang BK: Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Br J Cancer. 98:803–808. 2008. View Article : Google Scholar : PubMed/NCBI
8	Ashrafizadeh M, Zarrabi A, Hushmandi K, Kalantari M, Mohammadinejad R, Javaheri T and Sethi G: Association of the epithelial-mesenchymal transition (EMT) with cisplatin resistance. Int J Mol Sci. 21:40022020. View Article : Google Scholar : PubMed/NCBI
9	Avril T, Vauleon E and Chevet E: Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers. Oncogenesis. 6:e3732017. View Article : Google Scholar : PubMed/NCBI
10	Visioli F, Wang Y, Alam GN, Ning Y, Rados PV, Nör JE and Polverini PJ: Glucose-regulated protein 78 (Grp78) confers chemoresistance to tumor endothelial cells under acidic stress. PLoS One. 9:e1010532014. View Article : Google Scholar : PubMed/NCBI
11	Hu R, Warri A, Jin L, Zwart A, Riggins RB, Fang HB and Clarke R: NF-kappaB signaling is required for XBP1 (unspliced and spliced)-mediated effects on antiestrogen responsiveness and cell fate decisions in breast cancer. Mol Cell Biol. 35:379–390. 2015. View Article : Google Scholar : PubMed/NCBI
12	Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R and Mathieu V: Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol. 229:172–183. 2008. View Article : Google Scholar : PubMed/NCBI
13	Rao S, Oyang L, Liang J, Yi P, Han Y, Luo X, Xia L, Lin J, Tan S, Hu J, et al: Biological function of HYOU1 in tumors and other diseases. Onco Targets Ther. 14:1727–1735. 2021. View Article : Google Scholar : PubMed/NCBI
14	Jiang X, Liu B, Nie Z, Duan L, Xiong Q, Jin Z, Yang C and Chen Y: The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 6:742021. View Article : Google Scholar : PubMed/NCBI
15	Fu Y, Dominissini D, Rechavi G and He C: Gene expression regulation mediated through reversible m(6)A RNA methylation. Nat Rev Genet. 15:293–306. 2014. View Article : Google Scholar : PubMed/NCBI
16	Knuckles P, Lence T, Haussmann IU, Jacob D, Kreim N, Carl SH, Masiello I, Hares T, Villaseñor R, Hess D, et al: Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev. 32:415–429. 2018. View Article : Google Scholar : PubMed/NCBI
17	Pendleton KE, Chen B, Liu K, Hunter OV, Xie Y, Tu BP and Conrad NK: The U6 snRNA m(6)A Methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 169:824–835. e142017. View Article : Google Scholar : PubMed/NCBI
18	Mendel M, Chen KM, Homolka D, Gos P, Pandey RR, McCarthy AA and Pillai RS: Methylation of structured rna by the m(6)A writer METTL16 Is essential for mouse embryonic development. Mol Cell. 71:986–1000. e112018. View Article : Google Scholar : PubMed/NCBI
19	Wei J, Liu F, Lu Z, Fei Q, Ai Y, He PC, Shi H, Cui X, Su R, Klungland A, et al: Differential m(6)A, m(6)A(m), and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 71:973–985. e52018. View Article : Google Scholar : PubMed/NCBI
20	Mauer J, Luo X, Blanjoie A, Jiao X, Grozhik AV, Patil DP, Linder B, Pickering BF, Vasseur JJ, Chen Q, et al: Reversible methylation of m(6)A(m) in the 5′ cap controls mRNA stability. Nature. 541:371–375. 2017. View Article : Google Scholar : PubMed/NCBI
21	Su Y, Wang B, Huang J, Huang M and Lin T: YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer. Cell Prolif. 56:e134042023. View Article : Google Scholar : PubMed/NCBI
22	Wu S, Yun J, Tang W, Familiari G, Relucenti M, Wu J, Li X, Chen H and Chen R: Therapeutic m(6)A eraser ALKBH5 mRNA-Loaded exosome-liposome hybrid nanoparticles inhibit progression of colorectal cancer in preclinical tumor models. ACS Nano. 17:11838–11854. 2023. View Article : Google Scholar : PubMed/NCBI
23	Niu Y, Wan A, Lin Z, Lu X and Wan G: N (6)-Methyladenosine modification: A novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B. 8:833–843. 2018. View Article : Google Scholar : PubMed/NCBI
24	Qi L, Li Y, Qin Y, Shi G, Li T, Wang J, Chen L, Gu Y, Zhao W and Guo Z: An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy. Br J Cancer. 115:1513–1519. 2016. View Article : Google Scholar : PubMed/NCBI
25	Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, et al: Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 568:511–516. 2019. View Article : Google Scholar : PubMed/NCBI
26	Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, Dharia NV, Montgomery PG, Cowley GS, Pantel S, et al: Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 49:1779–1784. 2017. View Article : Google Scholar : PubMed/NCBI
27	Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, et al: Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41((Database issue)): D955–D961. 2013.PubMed/NCBI
28	Li Y, Xiao J, Bai J, Tian Y, Qu Y, Chen X, Wang Q, Li X, Zhang Y and Xu J: Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types. Mol Cancer. 18:1372019. View Article : Google Scholar : PubMed/NCBI
29	Liu J, Harada BT and He C: Regulation of gene expression by N(6)-methyladenosine in cancer. Trends Cell Biol. 29:487–499. 2019. View Article : Google Scholar : PubMed/NCBI
30	Huang H, Weng H and Chen J: m(6)A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer. Cancer Cell. 37:270–288. 2020. View Article : Google Scholar : PubMed/NCBI
31	Nombela P, Miguel-Lopez B and Blanco S: The role of m(6)A, m(5)C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 20:182021. View Article : Google Scholar : PubMed/NCBI
32	Qiu F, Liu Q, Xia Y, Jin H, Lin Y and Zhao X: Circ_0000658 knockdown inhibits epithelial-mesenchymal transition in bladder cancer via miR-498-induced HMGA2 downregulation. J Exp Clin Cancer Res. 41:222022. View Article : Google Scholar : PubMed/NCBI
33	Liao Y, Wang J, Jaehnig EJ, Shi Z and Zhang B: WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47:W199–W205. 2019. View Article : Google Scholar : PubMed/NCBI
34	Zhou Y, Zeng P, Li YH, Zhang Z and Cui Q: SRAMP: Prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 44:e912016. View Article : Google Scholar : PubMed/NCBI
35	Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, Qu LH and Yang JH: RMBase v2.0: Deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res. 46((D1)): D327–D334. 2018. View Article : Google Scholar : PubMed/NCBI
36	Yi Y, Zhao Y, Huang Y and Wang D: A brief review of RNA-protein interaction database resources. Noncoding RNA. 3:62017.PubMed/NCBI
37	Hochberg Y and Benjamini Y: More powerful procedures for multiple significance testing. Stat Med. 9:811–818. 1990. View Article : Google Scholar : PubMed/NCBI
38	Tsukamoto Y, Kuwabara K, Hirota S, Ikeda J, Stern D, Yanagi H, Matsumoto M, Ogawa S and Kitamura Y: 150-kD oxygen-regulated protein is expressed in human atherosclerotic plaques and allows mononuclear phagocytes to withstand cellular stress on exposure to hypoxia and modified low density lipoprotein. J Clin Invest. 98:1930–1941. 1996. View Article : Google Scholar : PubMed/NCBI
39	Giffin L, Yan F, Major MB and Damania B: Modulation of Kaposi's sarcoma-associated herpesvirus interleukin-6 function by hypoxia-upregulated protein 1. J Virol. 88:9429–9441. 2014. View Article : Google Scholar : PubMed/NCBI
40	Kuwabara K, Matsumoto M, Ikeda J, Hori O, Ogawa S, Maeda Y, Kitagawa K, Imuta N, Kinoshita T and Stern DM: Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J Biol Chem. 271:5025–5032. 1996. View Article : Google Scholar : PubMed/NCBI
41	Li X, Zhang NX, Ye HY, Song PP, Chang W, Chen L, Wang Z, Zhang L and Wang NN: HYOU1 promotes cell growth and metastasis via activating PI3K/AKT signaling in epithelial ovarian cancer and predicts poor prognosis. Eur Rev Med Pharmacol Sci. 23:4126–4135. 2019.PubMed/NCBI
42	Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE and Moroni M: HYOU1/Orp150 expression in breast cancer. Med Sci Monit. 13:BR231–BR239. 2007.PubMed/NCBI
43	Liu J and Wang Y: Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis. Bioengineered. 12:8753–8767. 2021. View Article : Google Scholar : PubMed/NCBI
44	Zhou Y, Liao Q, Li X, Wang H, Wei F, Chen J, Yang J, Zeng Z, Guo X, Chen P, et al: HYOU1, regulated by LPLUNC1, is up-regulated in nasopharyngeal carcinoma and associated with poor prognosis. J Cancer. 7:367–376. 2016. View Article : Google Scholar : PubMed/NCBI
45	Desrosiers R, Friderici K and Rottman F: Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975. 1974. View Article : Google Scholar : PubMed/NCBI
46	Saletore Y, Meyer K, Korlach J, Vilfan ID, Jaffrey S and Mason CE: The birth of the Epitranscriptome: Deciphering the function of RNA modifications. Genome Biol. 13:1752012. View Article : Google Scholar : PubMed/NCBI
47	Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian SB and Jaffrey SR: 5′ UTR m(6)A promotes cap-independent translation. Cell. 163:999–1010. 2015. View Article : Google Scholar : PubMed/NCBI
48	Dong Z, Liu LH, Han B, Pincheira R and Zhang JT: Role of eIF3 p170 in controlling synthesis of ribonucleotide reductase M2 and cell growth. Oncogene. 23:3790–3801. 2004. View Article : Google Scholar : PubMed/NCBI
49	Su R, Dong L, Li Y, Gao M, He PC, Liu W, Wei J, Zhao Z, Gao L, Han L, et al: METTL16 exerts an m(6)A-independent function to facilitate translation and tumorigenesis. Nat Cell Biol. 24:205–216. 2022. View Article : Google Scholar : PubMed/NCBI
50	Xu X, Han L, Yang H, Duan L, Zhou B, Zhao Y, Qu J, Ma R, Zhou H and Liu Z: The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients. Lung Cancer. 79:65–72. 2013. View Article : Google Scholar : PubMed/NCBI